Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
0 hedge funds and large institutions have $0 invested in Celyad Oncology SA American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $5.9K → $0 (-$5.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$5.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| – | -$5.9K | -9,000 | Closed |
|
CYAD Hedge Fund Activity: Q4 2023 in Review
0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2023, worth a combined $0 — down 100% from $5.9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CYAD and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was RhumbLine Advisers, exiting entirely with an estimated $5.9K sold.
- 0 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2023, down from 1 in Q3 2023.
- Funds reported $0 of Celyad Oncology SA American Depositary Shares stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Celyad Oncology SA American Depositary Shares seller in Q4 2023 was RhumbLine Advisers, an estimated $5.9K sold.
Based on aggregated 13F filings for Q4 2023.